Difference between revisions of "Interferon alfa-2a (Roferon-A)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Squamous cell carcinoma (SCC)" to "Cutaneous squamous cell carcinoma") |
Warner-admin (talk | contribs) m (Text replacement - "http://hemonc.org" to "https://hemonc.org") |
||
| (20 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood.<ref name="insert">[http://www.gene.com/gene/products/information/roferon-a/pdf/pi.pdf Interferon alfa-2a (Roferon-A) package insert]</ref><ref>[ | + | Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood.<ref name="insert">[http://www.gene.com/gene/products/information/roferon-a/pdf/pi.pdf Interferon alfa-2a (Roferon-A) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/interferonalfa-2a.pdf Interferon alfa-2a (Roferon-A) package insert (locally hosted backup)]</ref> |
<br>Route: SC | <br>Route: SC | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is established ''(work in progress)''== | ||
| + | *[[Chronic myeloid leukemia]] | ||
| + | *[[Hairy cell leukemia]] | ||
| + | *[[Renal cell carcinoma]] | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[ | + | *[[Kaposi sarcoma]] |
| − | + | *[[Neuroendocrine tumor]] | |
| − | |||
| − | *[[Neuroendocrine | ||
| − | |||
*[[Cutaneous squamous cell carcinoma]] | *[[Cutaneous squamous cell carcinoma]] | ||
| + | |||
| + | ==Diseases for which it was used== | ||
| + | *[[Follicular lymphoma - historical|Follicular lymphoma]] | ||
| + | *[[Melanoma - historical|Melanoma]] | ||
| + | *[[Multiple myeloma - historical|Multiple myeloma]] | ||
==Patient drug information== | ==Patient drug information== | ||
| + | *[http://www.gene.com/gene/products/information/roferon-a/pdf/pi.pdf Interferon alfa-2a (Roferon-A) package insert]<ref name="insert"></ref> | ||
*[http://chemocare.com/BIO/interferon_alfa.asp Interferon alfa-2a (Roferon-A) patient drug information (Chemocare)]<ref>[http://chemocare.com/BIO/interferon_alfa.asp Interferon alfa-2a (Roferon-A) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/BIO/interferon_alfa.asp Interferon alfa-2a (Roferon-A) patient drug information (Chemocare)]<ref>[http://chemocare.com/BIO/interferon_alfa.asp Interferon alfa-2a (Roferon-A) patient drug information (Chemocare)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *1986-06-04: Initial FDA approval for treatment of patients 18 years of age or older with [[hairy cell leukemia]] ''(Based on N2752)'' |
| + | *Uncertain date: In addition, it is indicated for chronic phase, Philadelphia chromosome (Ph) positive [[Chronic myeloid leukemia|chronic myelogenous leukemia (CML)]] patients who are minimally pretreated (within 1 year of diagnosis). ''(Based on DM 84-38 & MI400)'' | ||
==Also known as== | ==Also known as== | ||
| − | *'''Brand name:''' Roferon-A | + | *'''Brand name:''' Laroferon, Roferon-A |
==References== | ==References== | ||
| Line 28: | Line 37: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Subcutaneous medications]] | [[Category:Subcutaneous medications]] | ||
| − | [[Category: | + | [[Category:Interferon alfas]] |
| − | [[Category:Chronic | + | [[Category:Chronic myeloid leukemia medications]] |
| − | [[Category: | + | [[Category:Hairy cell leukemia medications]] |
| − | [[Category: | + | [[Category:Kaposi sarcoma medications]] |
[[Category:Neuroendocrine tumor medications]] | [[Category:Neuroendocrine tumor medications]] | ||
[[Category:Renal_cell_carcinoma medications]] | [[Category:Renal_cell_carcinoma medications]] | ||
[[Category:Cutaneous squamous cell carcinoma medications]] | [[Category:Cutaneous squamous cell carcinoma medications]] | ||
| + | |||
| + | [[Category:Follicular lymphoma medications (historic)]] | ||
| + | [[Category:Melanoma medications (historic)]] | ||
| + | [[Category:Multiple myeloma medications (historic)]] | ||
[[Category:FDA approved in 1986]] | [[Category:FDA approved in 1986]] | ||
Revision as of 19:29, 23 June 2024
General information
Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood.[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is established (work in progress)
Diseases for which it is used
Diseases for which it was used
Patient drug information
- Interferon alfa-2a (Roferon-A) package insert[1]
- Interferon alfa-2a (Roferon-A) patient drug information (Chemocare)[3]
History of changes in FDA indication
- 1986-06-04: Initial FDA approval for treatment of patients 18 years of age or older with hairy cell leukemia (Based on N2752)
- Uncertain date: In addition, it is indicated for chronic phase, Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) patients who are minimally pretreated (within 1 year of diagnosis). (Based on DM 84-38 & MI400)
Also known as
- Brand name: Laroferon, Roferon-A
References
Categories:
- Drugs
- Subcutaneous medications
- Interferon alfas
- Chronic myeloid leukemia medications
- Hairy cell leukemia medications
- Kaposi sarcoma medications
- Neuroendocrine tumor medications
- Renal cell carcinoma medications
- Cutaneous squamous cell carcinoma medications
- Follicular lymphoma medications (historic)
- Melanoma medications (historic)
- Multiple myeloma medications (historic)
- FDA approved in 1986